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Background
The major challenge facing both antibody and T cell-
eliciting vaccines against HIV-1 is the extreme variabil-
ity of the HIV-1 genome: a successful vaccine has to
effectively target diverse HIV-1 strains circulating in the
population and then must deal with ongoing virus
escape in infected individuals. To address these issues,
we assembled a vaccine immunogen HIVconsv from the
functionally most conserved regions (not epitopes) of
the HIV-1 proteome.
Methods
A gene coding for the HIVconsv immunogen was
inserted into plasmid DNA (D), modified vaccinia virus
Ankara (MVA; M) and non-replicating adenovirus of a
chimpanzee origin ChAdV-63 (C). Currently, combined
heterologous prime-boost regimens of these vaccines,
namely CM, DDDCM and DDDMC, are being evaluated
in a phase I/IIa trial HIV-CORE002 in healthy HIV-1/2-
negative volunteers in Oxford.
Results
Preliminary data indicate that the vaccines are well toler-
ated and show high immunogenicity. Following the CM
regimen, vaccine-induced T cell frequencies reached a
median of 5150 (range 1475 to 16495) SFU/106 PMBC ex
vivo one week post MVA vaccination. DNA priming
increased subsequent T cell responses to ChAdV-63 vacci-
nation (median: C 577 and DDDC 1328 SFU/106 PBMC)
and ELISpot responses again peaked 1 week following
MVA (median 4500; range 2260-7960 SFU/106 PBMC).
Matrix analyses of the participants following CM vaccina-
tion showed that T cells responded to a range of peptides
across the length of HIVconsv. The CM regimen elicited
IFN-g in both CD4+ and CD8+ T cell subsets and poly-
functional (IFN-g & TNF-a) responses to HIVconsv
peptides.
Conclusion
Presented data will be very much work in progress.
Nevetheless, the HIVconsv vaccines have so far induced
T cell responses superior to other HIV-1 vaccine candi-
dates tested to date. ChAdV-63 is the first adenovirus of
chimp origin delivering an HIV-1-derived immunogen
that has reached the clinic.
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